• Citizens reiterated its Market Outperform rating on the stock with a $9.00 price target, suggesting significant potential upside from current levels.
  • The company today launched its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool for healthcare provider and patient engagement.
  • This positive news, coupled with the company's long-term AI growth initiatives, is driving the stock's performance.